Semax

Mechanism of action

Semax is a 7-amino-acid synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP) derived from the central biologically active region of adrenocorticotropic hormone (ACTH) by truncation of the 4-10 sequence and addition of a C-terminal Pro-Gly-Pro tripeptide that confers proteolytic stability. The native ACTH 4-10 sequence (MEHFRWG) was identified in the mid-20th century as the minimal region of ACTH retaining nootropic and neuroprotective activity without the corticotropic (adrenocortical-stimulating) effect of the full ACTH molecule. Semax represents a deliberate medicinal-chemistry optimisation of this fragment for stability and nootropic potency. The molecular mechanism of Semax remains incompletely characterised but appears to involve multiple coordinated effects on the central nervous system. Direct upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus has been demonstrated in rodent models within 90-180 minutes of intranasal administration, with effects sustained for several hours. The signalling cascade appears to involve melanocortin-receptor-mediated transcriptional effects (Semax retains some MC4R activity but lacks the MC2R/ACTH-receptor activation responsible for corticotropic effects), modulation of enkephalinase activity (paralleling Selank's mechanism on a different scale), and effects on the BDNF/TrkB and NGF/TrkA receptor signalling cascades that drive hippocampal long-term potentiation and synaptic plasticity. Downstream of BDNF and NGF upregulation, Semax produces effects on hippocampal long-term potentiation, dendritic spine density, and the broader structural correlates of learning and memory. In rodent behavioural models — Morris water maze, novel object recognition, contextual fear conditioning — Semax administration produces dose-dependent improvements in spatial learning, recognition memory, and stress-resilience phenotypes. Effects on the noradrenergic system (modest increases in central norepinephrine) and the dopaminergic system (modulation of prefrontal cortex dopamine) have been described and may contribute to the attentional and executive-function effects reported in human cognitive studies. A mechanistically critical feature of Semax pharmacology is the intranasal delivery route. As a 7-amino-acid peptide of moderate hydrophilicity, Semax has negligible blood-brain barrier penetration after peripheral administration. The intranasal route exploits the olfactory and trigeminal nerve pathways that allow direct access to the central nervous system, bypassing the BBB. Pharmacokinetic studies in rodents have demonstrated that intranasal Semax achieves cerebrospinal fluid concentrations 10-50 fold higher than equivalent intravenous doses, with sustained hippocampal tissue exposure that supports the 4-8 hour functional effect duration observed in cognitive endpoints. The intranasal route also avoids first-pass hepatic metabolism and reduces systemic exposure to a fraction of the central exposure — minimising the off-target peripheral effects that would otherwise complicate the cognitive-research framework. A practical formulation feature is that the standard Russian-marketed product (Semax 0.1% nasal drops) is supplied in single-use plastic vials at low concentrations designed for chronic intranasal administration. Higher-concentration preparations (1% nasal drops) are reserved for acute stroke applications under medical supervision. The dose-response relationship in cognitive applications is approximately linear over the standard research dose range but plateaus at higher doses, consistent with the saturation kinetics expected for receptor-mediated mechanisms.

Intranasal Semax administration upregulates hippocampal BDNF and NGF mRNA expression within 90-180 minutes of administration in rodent models (Dolotov et al., Brain Res 2006) — establishing the molecular basis of the nootropic effect and supporting the intranasal-delivery rationale that bypasses the blood-brain barrier limitation common to peripheral peptide pharmacology.

— Notable finding

Research history

Semax was developed by the Russian Institute of Molecular Genetics (Moscow) in the 1980s as part of a long-running Soviet and post-Soviet research programme exploring ACTH-fragment-derived nootropic peptides. The molecular design originated from systematic structure-activity analysis of the ACTH 4-10 sequence and related fragments, with the goal of identifying compounds retaining the neurotropic effects of ACTH without the corticotropic adrenal-axis activation. The Pro-Gly-Pro C-terminal extension was added specifically to confer proteolytic stability against brain peptidases, extending the effective duration of action. Clinical development in the Soviet Union and subsequently in Russia and several CIS (Commonwealth of Independent States) jurisdictions established Semax as a registered prescription medicine for several indications: acute ischaemic stroke (initial registration in the early 1990s, with subsequent acute-care clinical use in Russian neurology), transient ischaemic attack, cognitive impairment in various contexts, and pediatric attention-deficit and learning-disability indications. The Russian regulatory framework accepts a different evidence base than the FDA or MHRA — Semax registration did not require Western-standard large-scale randomised trials, and the published clinical literature is dominated by Russian-language publications that have not been subject to extensive Western peer review. The compound has been studied in animal stroke models, traumatic brain injury models, and cognitive-decline models across the 1990s to 2020s, with a substantial pre-clinical publication record. Independent verification of the clinical efficacy claims by Western research groups has been limited but generally supportive of the underlying mechanism (BDNF/NGF upregulation, hippocampal effects on learning and memory). Semax has not been pursued for FDA, EMA, or MHRA marketing authorisation. The off-patent nature of the molecule, the geopolitical complexity of Russian-pharmaceutical regulatory translation, and the absence of a Western sponsor have together prevented progression toward Western licensure. The compound exists in Russia and CIS countries as a registered prescription medicine, and in Western jurisdictions including the UK as an unlicensed research-chemical and grey-market nootropic substance. In the research-chemical-community context, Semax has gained substantial visibility since the late 2010s as the prototype 'nootropic peptide' alongside Selank. Research-chemical supply is widely available at moderate cost, typically in lyophilised form for laboratory reconstitution as intranasal drops.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Semax has the largest clinical-use safety dataset of any cognitive research peptide outside of cerebrolysin, accumulated through 30+ years of Russian clinical use across stroke, cognitive impairment, and paediatric indications. The acute and chronic adverse-event profile reported in Russian post-marketing surveillance is favourable: mild and transient adverse effects predominate, with nasal irritation (mild stinging, runny nose) being the most common; occasional mild headache; rare reports of transient sleep disturbance with high-dose protocols. No clinically significant changes in routine haematology, biochemistry, or vital signs have been documented in the Russian clinical experience. The peptide's selective preservation of nootropic activity without ACTH-receptor-mediated corticotropic effect is the defining safety feature. Semax does not produce the cortisol elevation, hypothalamic-pituitary-adrenal axis disruption, or the metabolic adverse-event profile that would be expected from full ACTH or from less-selective ACTH fragments. This selectivity is the principal reason Semax is suitable for chronic cognitive-enhancement protocols rather than only acute neurology applications. Western pre-clinical safety data are limited but consistent with the Russian clinical experience. Acute and sub-chronic rodent toxicology studies have not identified dose-limiting organ-specific toxicity at doses materially above the human clinical equivalent. The intranasal delivery route limits systemic exposure to a small fraction of the central exposure, further reducing the off-target peripheral safety concerns that would apply to systemic peptide administration. Theoretical safety considerations centre on the chronic-dosing pharmacology of BDNF and NGF upregulation. Sustained neurotrophin elevation could theoretically affect peripheral sympathetic and sensory neuron function (NGF effects), and the long-term consequences of chronic BDNF/TrkB pathway activation in adult humans are incompletely characterised. The Russian clinical experience has not surfaced concerning signals in these domains, but the chronic-dosing record is not equivalent to a formal Western Phase III/IV regulatory dataset. The pediatric indication in Russia is particularly notable from a safety perspective — chronic Semax use in children with attention-deficit and learning-disability conditions has produced an extensive paediatric safety record that has not surfaced significant developmental or growth concerns. The translatability of this Russian pediatric experience to Western regulatory standards is limited but the underlying data are favourable.

UK regulatory status

Semax is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any Western jurisdiction. It is a registered prescription medicine in Russia and several Commonwealth of Independent States (CIS) jurisdictions; this registration does not confer UK regulatory status. Semax is not a controlled substance under the Misuse of Drugs Act 1971. Possession of research-grade material for bona fide in-vitro and animal research is generally unrestricted in the UK. Supply or administration of Semax to humans outside an authorised UK clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence — the Russian/CIS registration does not authorise UK supply or use. Semax is not currently on the WADA Prohibited List. Its mechanism (nootropic and neurotrophic) does not currently fall within any WADA category, though athletes should verify the current annual Prohibited List as classifications can change with emerging compounds. For animal research under ASPA, Semax work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit. UK individuals occasionally obtain Semax via personal import from Russian or Eastern European pharmacies (where it is dispensed as a prescription medicine in those jurisdictions). The Border Force and MHRA position on personal-import unlicensed medicines is restrictive in principle though enforcement intensity is variable; researchers should consult appropriate regulatory channels rather than relying on this practical position.

Frequently asked questions